Microbot Medical (NASDAQ: MBOT) awards CEO 480,000 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Gadot Harel reported acquisition or exercise transactions in this Form 4 filing.
Microbot Medical Inc. reported that Chairman, President and CEO Harel Gadot received a grant of stock options covering 480,000 shares of common stock. These options were awarded under the company’s 2020 Omnibus Performance Award Plan.
According to the grant terms, 25% of the option vests and becomes exercisable on August 18, 2026. The remaining 75% vests and becomes exercisable in equal installments on a quarterly basis over the following 30 months, subject to the plan’s provisions on possible acceleration or forfeiture.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Gadot Harel
Role
Chairman, President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 480,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 480,000 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transaction did Microbot Medical (MBOT) report for Harel Gadot?
Microbot Medical reported a grant of stock options to CEO Harel Gadot covering 480,000 shares of common stock. The options were awarded under the company’s 2020 Omnibus Performance Award Plan, reflecting equity-based executive compensation rather than an open-market share purchase or sale.
How many stock options were granted to the MBOT CEO in this Form 4?
The CEO of Microbot Medical received stock options for 480,000 shares of common stock. This entire amount represents a single award, with vesting scheduled over several years under the 2020 Omnibus Performance Award Plan, aligning executive incentives with longer-term company performance.
What is the vesting schedule for Harel Gadot’s 480,000 MBOT stock options?
The options vest in two phases: 25% of the 480,000-share grant vests and becomes exercisable on August 18, 2026. The remaining 75% vests in equal quarterly installments over the next 30 months, subject to potential acceleration or forfeiture under the plan’s terms.
Is the insider transaction in MBOT’s Form 4 a purchase or an award?
The reported transaction is an award of stock options, classified as a grant or other acquisition. It is not an open-market purchase or sale, but an equity compensation grant under Microbot Medical’s 2020 Omnibus Performance Award Plan to its Chairman, President and CEO.
Does Harel Gadot directly own the MBOT stock options reported in this filing?
Yes. The Form 4 shows the 480,000 stock options as directly owned by Harel Gadot. The ownership type is listed as direct, indicating the award is attributed personally to him rather than to an indirect entity such as a trust or partnership.
What plan governs the stock option award reported for MBOT’s CEO?
The stock option grant to Microbot Medical’s CEO is governed by the company’s 2020 Omnibus Performance Award Plan, as amended. The vesting schedule, exercisability, and any acceleration or forfeiture provisions follow the detailed terms set out in that compensation plan.